ISM is a rare mast cell neoplasm that is unpredictable in nature, presenting with a wide range of symptoms across multiple organ systems^1,2

ISM is the most common subtype of SM, accounting for ~90% of all SM cases³

Patients with ISM experience high symptom burden and impaired daily functioning despite best supportive care^1,2

Symptoms of ISM (N=164)^4*

Graph indicating symptoms of ISM based on a Dutch cohort of 164

*Based on a Dutch cohort of 164 patients with ISM.⁴

Many patients with ISM report severe symptom burden despite taking several medications for managing their symptoms²

Did you know?

A small subset of patients with ISM (~3%) may progress to more advanced forms of SM^5**

**Based on the Trizuljak 2020 study of 813 patients with ISM in the ECNM registry dataset to compare the prognosis of typical ISM with other subtypes.⁶

Click here to learn more about AYVAKYT

About AYVAKYT

ECNM=European Competence Network on Mastocytosis.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the product SmPC for how to report adverse reactions.

References

Gotlib J, et al. NEJM Evid. 2023;2(6):EVIDoa2200339.
Mesa RA, et al. Cancer. 2022;128(20):3700–3708.
Gülen T, et al. J Intern Med. 2016;279(3):211–228.
van Anrooij B, et al. Allergy. 2016;71(11):1585–1593.
Mesa RA, et al. Cancer. 2022;128(20):3691–3699.
Trizuljak J, et al. Allergy. 2020;75(8):1927–1938.

Indolent Systemic Mastocytosis

ISM is a rare mast cell neoplasm that is unpredictable in nature, presenting with a wide range of symptoms across multiple organ systems1,2

Patients with ISM experience high symptom burden and impaired daily functioning despite best supportive care1,2

Symptoms of ISM (N=164)4*

Many patients with ISM report severe symptom burden despite taking several medications for managing their symptoms2